Skip to main content

Advertisement

SpringerLink
Log in

Relations Between Pathological Markers and Radioiodine Scan and 18F-FDG PET/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases

  • Original Article
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to investigate relationships between the immunohistochemical results and radioiodine scan and 18F-FDG PET findings in papillary thyroid cancer (PTC) patients with recurrent cervical nodal metastases.

Methods

A total of 46 PTC patients who had undergone a radioiodine scan and/or 18F-FDG PET/CT and a subsequent operation on recurrent cervical lymph nodes were enrolled. Twenty-seven patients underwent 18F-FDG PET/CT, 8 underwent radioiodine scans, and 11 underwent both scans. In all surgical specimens, the immunoexpressions of thyroglobulin (Tg), sodium-iodide symporter (NIS), glucose transporter 1 (Glut-1), and somatostatin receptor 1 and 2A (SSTR1 and SSTR2A) were assessed, and associations between these expressions and radioiodine scan and 18F-FDG PET findings were evaluated.

Results

Of the 38 patients who underwent 18F-FDG PET/CT, all patients with weak Tg expression had positive 18F-FDG uptake, while only 45 % of the patients with moderate or strong Tg expression showed positive uptake (p = 0.01). The proportion of patients with positive 18F-FDG uptake increased as the degree of Glut-1 expression with luminal accentuation increased. Of the 19 patients who underwent a radioiodine scan, the proportion with positive radioiodine uptake was greater among patients with strong NIS and SSTR2A expression than among patients expressing these markers at weak levels (p = 0.04 for all). All three patients with weak Tg expression were negative for radioiodine uptake.

Conclusion

The 18F-FDG uptakes of recurrent cervical nodes are related to strong Glut-1 expression with luminal accentuation and weak Tg expression, whereas radioiodine uptake is related to the strong expressions of NIS and SSTR2A.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Pelizzo MR, Merante BI, Toniato A, Pagetta C, Casal IE, Mian C, et al. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol. 2008;33:359–79.

    CAS  PubMed  Google Scholar 

  2. Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imag. 2006;50:78–87.

    CAS  Google Scholar 

  3. Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol. 2000;143:623–7.

    Article  CAS  PubMed  Google Scholar 

  4. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab. 1998;83:2493–6.

    CAS  PubMed  Google Scholar 

  5. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol. 1998;138:249–52.

    Article  CAS  PubMed  Google Scholar 

  6. Wu LM, Gu HY, Qu XH, Zheng J, Zhang W, Yin Y, et al. The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: a meta-analysis. Eur J Radiol. 2012;81:1798–805.

    Article  PubMed  Google Scholar 

  7. Lee DW, Ji YB, Sung ES, Park JS, Lee YJ, Park DW, et al. Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. Eur J Surg Oncol. 2013;39:191–6.

    Article  CAS  PubMed  Google Scholar 

  8. Miller ME, Chen Q, Elashoff D, Abemayor E, St JM. Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck. 2010;33:562–5.

    Article  Google Scholar 

  9. Middendorp M, Selkinski I, Happel C, Kranert WT, Grunwald F. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imag. 2010;54:76–83.

    CAS  Google Scholar 

  10. Ciampi R, Vivaldi A, Romei C, Del Guerra A, Salvadori P, Cosci B. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol. 2008;291:57–62.

    Article  CAS  PubMed  Google Scholar 

  11. Usuda K, Sagawa M, Aikawa H, Ueno M, Tanaka M, Machida Y, et al. Correlation between glucose transporter-1 expression and 18F-fluoro-2-deoxyglucose uptake on positron emission tomography in lung cancer. Gen Thorac Cardiovasc Surg. 2010;58:405–10.

    Article  PubMed  Google Scholar 

  12. Hiyoshi Y, Watanabe M, Imamura Y, Nagai Y, Baba Y, Yoshida N, et al. The relationship between the glucose transporter type 1 expression and F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma. Oncology. 2009;76:286–92.

    Article  CAS  PubMed  Google Scholar 

  13. Rodrigues M, Li S, Gabriel M, Heute D, Greifeneder M, Virgolini I. 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J Clin Endocrinol Metab. 2006;91:3997–4000.

    Article  CAS  PubMed  Google Scholar 

  14. Ordonez NG, El-Naggar AK, Hickey RC, Samaan NA. Anaplastic thyroid carcinoma. immunocytochemical study of 32 cases. Am J Clin Pathol. 1991;96:15–24.

    CAS  PubMed  Google Scholar 

  15. Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg. 2007;142:717–27.

    Article  CAS  PubMed  Google Scholar 

  16. Chung JKYH, Kang JH, Lee HY, Kang KW. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging. 2010;44:4–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Schonberger J, Ruschoff J, Grimm D, Marienhagen J, Rummele P, Meyringer R, et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid. 2002;12:747–54.

    Article  PubMed  Google Scholar 

  18. Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf). 2008;68:108–16.

    Article  CAS  Google Scholar 

  19. Hooft L, van der Veldt AA, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ. [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab. 2005;90:328–34.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang JZ, Behrooz A, Ismail-Beigi F. Regulation of glucose transport by hypoxia. Am J Kidney Dis. 1999;34:189–202.

    Article  CAS  PubMed  Google Scholar 

  21. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, et al. Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep. 2005;14:1499–504.

    CAS  PubMed  Google Scholar 

  22. Haber RS, Weiser KR, Pritsker A, Reder I, Burstein DE. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid. 1997;7:363–7.

    Article  CAS  PubMed  Google Scholar 

  23. Pisarek H, Stepien T, Kubiak R, Borkowska E, Pawlikowski M. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res. 2009;2:1.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Druckenthaner M, Schwarzer C, Ensinger C, Gabriel M, Prommegger R, Riccabona G, et al. Evidence for Somatostatin receptor 2 in thyroid tissue. Regul Pept. 2007;138:32–9.

    Article  CAS  PubMed  Google Scholar 

  25. Kurdziel K, Ravizzini G, Croft B, Tatum J, Choyke P, Kobayashi H. The evolving role of nuclear molecular imaging in cancer. Expert Opin Med Diagn. 2008;2:829–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Jung YH, Hah JH, Sung MW, Kim KH, Cho SY, Jeon YK. Reciprocal immunohistochemical expression of sodium/iodide symporter and hexokinase I in primary thyroid tumors with synchronous cervical metastasis. Laryngoscope. 2009;119:541–8.

    Article  CAS  PubMed  Google Scholar 

  27. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888–91.

    CAS  PubMed  Google Scholar 

  28. Iwano S, Kato K, Nihashi T, Ito S, Tachi Y, Naganawa S. Comparisons of I-123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue and metastases of differentiated thyroid cancer. Ann Nucl Med. 2009;23:777–82.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University College of Medicine. (20100028340)

Conflict of Interest

Jeong Won Lee, Hye Sook Min, Sang Mi Lee, Hyun Woo Kwon and June-Key Chung declare that they have no conflict of interest.

Informed Consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. The study design and exemption of informed consent were approved by the Institutional Review Board of Seoul National University Hospital.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Catholic Kwandong University International St. Mary’s Hospital, Seoul, Korea

    Jeong Won Lee

  2. Department of Pathology, Seoul National University Hospital, Seoul, Korea

    Hye Sook Min

  3. Department of Nuclear Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea

    Sang Mi Lee

  4. Department of Nuclear Medicine, Seoul National University College of Medicine, Medicine, 101 Daehang-Ro, Jongno-Gu, Seoul, 110-744, Korea

    Hyun Woo Kwon & June-Key Chung

  5. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

    June-Key Chung

Authors
  1. Jeong Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hye Sook Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sang Mi Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hyun Woo Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. June-Key Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to June-Key Chung.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, J.W., Min, H.S., Lee, S.M. et al. Relations Between Pathological Markers and Radioiodine Scan and 18F-FDG PET/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases. Nucl Med Mol Imaging 49, 127–134 (2015). https://doi.org/10.1007/s13139-015-0324-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-015-0324-6

Keywords

Search

Navigation